|
Originally published In Press as doi:10.1074/jbc.M001887200 on April 25, 2000
J. Biol. Chem., Vol. 275, Issue 27, 20578-20587, July 7, 2000
Regulated Association of Microtubule-associated Protein 2 (MAP2) with Src and Grb2: Evidence for MAP2 as a Scaffolding
Protein*
Rita W. L.
Lim and
Shelley
Halpain
From the Department of Cell Biology, The Scripps Research
Institute, La Jolla, California 92037
Received for publication, March 7, 2000
 |
ABSTRACT |
Microtubule-associated protein 2 (MAP2) and tau,
which is involved in Alzheimer's disease, are major cytoskeletal
proteins in neurons. These proteins are involved in microtubule
assembly and stability. To further characterize MAP2, we took a
strategy of identifying potential MAP2 binding partners. The low
molecular weight MAP2c protein has 11 PXXP motifs that are
conserved across species, and these PXXP motifs could be
potential ligands for Src homology 3 (SH3) domains. We tested for MAP2
interaction with SH3 domain-containing proteins. All neuronal MAP2
isoforms bound specifically to the SH3 domains of c-Src and Grb2 in an
in vitro glutathione S-transferase-SH3
pull-down assay. Interactions between endogenous proteins were
confirmed by co-immunoprecipitation using brain lysate. All three
proteins were also found co-expressed in neuronal cell bodies and
dendrites. Surprisingly, the SH3 domain-binding site was mapped to the
microtubule-binding domain that contains no PXXP motif. Src
bound primarily the soluble, non-microtubule-associated MAP2c in
vitro. This specific MAP2/SH3 domain interaction was inhibited by
phosphorylation of MAP2c by the mitogen-activated protein kinase
extracellular signal-regulated kinase 2 but not by protein
kinase A. This phosphorylation-regulated association of MAP2 with
proteins of intracellular signal transduction pathways suggests a
possible link between cellular signaling and neuronal cytoskeleton,
with MAP2 perhaps acting as a molecular scaffold upon which
cytoskeleton-modifying proteins assemble and dissociate in response to
neuronal activity.
 |
INTRODUCTION |
In the mammalian nervous system, the neuron-specific
microtubule-associated protein
MAP21 regulates microtubule
dynamics (1) and is attributed with an important role in neurite
outgrowth and dendrite development (2-6). MAP2 belongs to a family of
heat stable microtubule-associated proteins found in eukaryotic cells.
Other family members include MAP4, a ubiquitous protein, and tau, a
neuronal protein involved in Alzheimer's disease (4, 5). Members of
this family share a common microtubule-binding domain (MTBD) consisting
of approximately 100-130 amino acid residues near the carboxyl
terminus of the molecule. The MTBD contains three or four tandem
imperfect repeats of 18 amino acid residues separated by a variable
inter-repeat region of approximately 12 amino acid residues (7).
Recently, tau has been shown to bind the Src family of non-receptor
tyrosine kinases (Src, Lyn, and Fyn (8)) and protein phosphatases PP1
and PP2A (9-11). The interactions among PP1, PP2A, tau, and
microtubules were postulated to regulate the phosphorylation state of
tau, and alterations to these interactions could lead to the
development of tauopathies seen in neurological diseases such as
Alzheimer's (12-14). This increasing body of evidence suggests that
microtubule-based structural proteins like MAP2 and tau could play
other physiological roles in addition to the regulation of microtubule assembly.
Like tau, MAP2 is a phosphoprotein, and its cellular activities are
regulated by phosphorylation. The phosphorylation state of MAP2 is
modulated by neural activity in vivo (15-20). In
vitro, several serine/threonine protein kinases and phosphatases
are capable of using MAP2 as a substrate (21-28). Tyrosine kinases such as insulin receptor kinase, epidermal growth factor receptor kinase, and Src have been reported to phosphorylate MAP2 in
vitro (29-31). Besides microtubules, several additional proteins
have been reported to interact with MAP2 in vitro, the best
characterized of which is the type II regulatory subunit of PKA
(32-34). Other proteins include F-actin (35-38), calmodulin (39), and
the mitochondrial outer membrane protein porin (40). The precise
binding sites on MAP2 for these proteins have yet to be identified.
Except for the MTBD at the carboxyl terminus and the type II regulatory
subunit of PKA binding region (30 amino acids) in the amino terminus of MAP2, the rest of the molecule ( 65%) has no assigned function. It is
possible that MAP2 possesses some as yet uncovered role in the neuron,
in addition to its contribution to cellular structural integrity.
This paper presents evidence of a novel interaction of MAP2 with the
non-receptor protein tyrosine kinase c-Src and the adaptor protein
Grb2. The data support the emerging idea that members of signal
transduction pathways interact with microtubule-associated proteins and
could thereby regulate the organization and dynamics of the cytoskeleton.
 |
EXPERIMENTAL PROCEDURES |
Materials--
DNA restriction enzymes, PKA, MAPK (extracellular
signal-regulated kinase 2, p42), and phosphotyrosine monoclonal
antibody P-Tyr-100 were from New England Biolabs. The Pfu
DNA polymerase and Escherichia coli strains XL1 Blue, XL2
Blue, DH5 , JM109, and BL21(DE3) were from Stratagene. Protein
expression vectors pET-3a, pET-11a, and pET-32a were from Novagen. The
pGEX-2T vector, glutathione-Sepharose, SP ion exchange resin,
HRP-conjugated goat anti-mouse and anti-rabbit antibodies, and thrombin
were from Amersham Pharmacia Biotech. Monoclonal anti-polyhistidine
antibody, HIS-1, anti-MAP2 antibody, HM2, PMSF, reduced glutathione,
protein A-Sepharose, ampicillin, carbenicillin, leupeptin, aprotinin, pepstatin A, benzamide, benzamidine, -caproic acid, GTP, ATP, L-glutamine, pyruvate, GSK-3 , and lysozyme were from
Sigma. Superfect reagent was from Qiagen. Paclitaxel was from
Calbiochem. Sypro Orange was from Bio-Rad. BCA protein assay reagent
was from Pierce. Nitrocellulose membranes (0.45 µm, BA-85) were from
Schleicher & Schuell. Alkaline phosphatase-conjugated goat anti-rabbit
and anti-mouse antibodies were from Promega. Alexa-568 conjugated goat
anti-mouse IgG and Alexa-488 conjugated goat anti-rabbit IgG were from
Molecular Probes. Rabbit anti-Src sc-18 and rabbit anti-Grb2 sc-255
antibodies were from Santa Cruz Biotechnology. Monoclonal
anti-phosphotyrosine antibody 4G10 was from Upstate Biotechnology.
HRP-conjugated recombinant anti-phosphotyrosine PY20 (RC20-HRP) and
monoclonal anti-Grb2 antibodies were from Transduction Laboratories.
Bovine tubulin was from Cytoskeleton Inc. Talon spin columns (0.5 ml)
were from CLONTECH Laboratories. [ -32P]ATP was from NEN Life Science Products.
Construction of Expression Vectors--
All molecular methods
were performed according to Ref. 41. Construction of the expression
plasmid pET3aMAP2c, which encodes the full-length rat MAP2c protein,
has been described (1). Mutant forms of MAP2c were made by PCR cloning
using pET3aMAP2c or one of the subsequently constructed expression
plasmids described below as PCR templates. The open reading frames in
all constructs were verified by automated DNA sequencing conducted at
Scripps Nucleic Acid Core facility with PE Biosystems instrument 373 A using the Taq DNA polymerase, fluorescence dye detection,
and dideoxy terminator chemistry (42). Custom designed primers with unique restriction enzyme recognition sites were used to amplify specific regions of MAP2c cDNA and to facilitate ligation of the amplified PCR fragments into expression vectors. DNA amplifications were conducted in a model 9600 DNA thermal cycler (PE Biosystems). The
amplification protocol consisted of 30 cycles of the following conditions: denaturation at 95 °C for 1 min, primer annealing at
57 °C for 1 min, and chain extension at 72 °C for 1 min (5 min
for the last cycle) with recombinant Pfu DNA polymerase
according to the manufacturer's procedure. The PCR fragments encoding
the amino acids 1-299, 1-310, 154-467, and 296-467 of MAP2c were
digested with NdeI and BamHI and ligated into a
previously NdeI/BamHI-digested pET-11a plasmid.
The PCR fragment encoding amino acids 300-400, the MTBD, was digested
with NcoI and BamHI and ligated into a previously
NcoI/BamHI-digested pET-32a plasmid. The new
constructs were transformed into cloning host E. coli strain
DH5 , XL-1 Blue, XL-2 Blue, or JM109 and were also transformed into
expression host E. coli BL21(DE3) by the CaCl2
transformation method. Stable transformants were selected on LB plates
supplemented with 50 µg/ml carbenicillin.
To make internal deletion MAP2c constructs, separate DNA fragments of
MAP2c were amplified by PCR and then ligated together. The expression
plasmid 134-141 encoding MAP2c, lacking the amino acids 134-141,
was made by amplifying the DNA sequence encoding the amino acids 1-133
and 142-467. Both PCR products were gel-purified and digested with
BssSI. The 1-133 fragment was further digested with
NdeI, whereas the 142-467 fragment was digested with
BamHI. The digested DNA fragments were gel-purified again
and ligated into the NdeI/BamHI-digested
expression vector pET-3a. The ligation of these two fragments
introduced an additional valine at the junction between the amino acids
133 and 142. The 134-141 construct was transformed into JM109 and
BL21(DE3). The expression plasmids 219-290, 290-297, and
290-400, which encode MAP2c lacking regions 219-290, 290-297, and
290-400, respectively, were constructed using a similar strategy,
except that the PCR products were initially digested with
BsiWI prior to digestion with NdeI or
BamHI. In making the double deletion construct 134-141,
219-290, a PCR fragment corresponding to the region 142-467,
219-290, was amplified from the 219-290 single deletion plasmid
described above. This PCR fragment was digested with BssSI
and BamHI, gel-purified, and then ligated to the
NdeI/BssSI-digested fragment 1-133. For the
double deletion construct 134-141, 290-297, a PCR fragment corresponding to the region 1-289, 134-141, was amplified from the
134-141 single deletion plasmid described above. This PCR fragment
was sequentially digested with BsiWI followed by
NdeI, gel-purified, and then ligated to the
BsiWI/BamHI-digested fragment 298-467. To
construct the 219-297 plasmid, the 219-290 plasmid was digested
with NdeI and BsiWI, and the larger fragment,
which encodes the region 1-218, was gel-purified. The 290-297
plasmid was digested with BsiWI and BamHI, and
the smaller fragment, which encodes the region 298-467, was
gel-purified. The 1-218 NdeI/BsiWI fragment was
ligated to the 298-467 BsiWI/BamHI fragment and
then inserted into an NdeI/BamHI-digested pET-3a
plasmid. To construct the triple deletion 134-141, 220-297
plasmid, the 134-141, 219-290 plasmid was digested with
NdeI and BsiWI, and the larger fragment, which
encodes the region 1-218, 134-141, was gel-purified. This fragment
was ligated to the 298-467 BsiWI/BamHI fragment
and then inserted into an NdeI/BamHI-digested
pET-3a plasmid. These constructs were transformed into cloning bacteria
E. coli JM109 and expression host bacteria BL21(DE3).
Expression and Purification of Recombinant MAP2c
Proteins--
Induction of protein expression in bacteria and
purification of full-length and mutant non-fusion MAP2c proteins were
performed as described (1), with modifications. The concentration of NaCl was reduced to 0.1 M. The boiled supernatant collected
was further purified by SP ion exchange chromatography. The supernatant was filtered through a 0.45 µm filter and loaded onto a 0.6 × 1.0-cm SP column pre-equilibrated with 5 ml of 50 mM sodium
acetate, pH 5.5, 1 mM EDTA, 1 mM EGTA, and 5 mM -mercaptoethanol (Buffer A) at room temperature. The
rMAP2c bound to the SP column at pH 5.5, whereas most of the bacterial
proteins were found in the run-through. The column was washed with 20 ml of Buffer A containing 0.15 M NaCl, and rMAP2c protein
was step eluted with Buffer A containing 0.3 M NaCl.
Fractions of 300 µl were collected and analyzed by SDS-PAGE.
Fractions containing rMAP2c were pooled and dialyzed against 500 ml of
50 mM Tris-HCl, pH 8, 1 mM EGTA, 1 mM EDTA, 0.02% NaN3, 1 mM
dithiothreitol, and 150 mM NaCl at 4 °C overnight,
divided into small aliquots, and stored at -80 °C. The rMAP2c
proteins obtained were of 90% purity, and the average yield was 0.7 mg/50 ml of bacterial culture.
The MAP2c MTBD fragment cloned into the expression plasmid pET-32a was
expressed as a histidine-tagged thioredoxin fusion protein
(HisTrxMTBD). The induction of HisTrxMTBD and the histidine-tagged thioredoxin (HisTrx) protein expression from pET-32a was initiated at
A600 = 0.6-0.9 with 1 mM
isopropyl-1-thio- -D-galactopyranoside. Protein
expression was allowed to proceed at 30 °C for 3 h. Bacteria harvested from a 50-ml culture was lysed in 10 ml of 20 mM
Tris-HCl, pH 8.0, 100 mM NaCl (Buffer B) supplemented with
1 mM PMSF, 10 µg/ml aprotinin, 10 µg/ml pepstatin A, 10 µg/ml leupeptin. Cell lysis using lysozyme and sonication were
performed as described (1). The lysate was centrifuged at 15,000 × g for 30 min at 4 °C. The supernatant was collected,
filtered through a 0.45 µm filter, and loaded onto a 0.5 × 1.5-cm Talon-NX column that had been pre-equilibrated with Buffer B. The column was washed with 5 ml of Buffer B followed by 5 ml of Buffer
B containing 10 mM imidazole, pH 8.0, and the
histidine-tagged protein was step eluted with Buffer B containing 100 mM imidazole, pH 8.0. Fractions of 500 µl were collected
and analyzed by SDS-PAGE. Fractions containing the histidine-tagged
protein were pooled, dialyzed against 250 ml of Buffer B with 5 mM EDTA and 0.02% NaN3 at 4 °C overnight, divided into small aliquots, and stored at -80 °C. The proteins were of 95% purity, and the average yield was 0.5 mg/50 ml of bacterial culture.
GST-SH3 Fusion Proteins and Thrombin Cleavage--
Expression
and purification of the GST and GST-SH3 fusion proteins using
glutathione-Sepharose beads were carried out according to the
manufacturer's procedure. A 5-µl aliquot of a ~50% (v/v) slurry
of protein-bound glutathione-Sepharose beads contained about 15-20
µg of GST-SH3 fusion protein as determined by SDS-PAGE. For the
microtubule binding competition experiments, the GST-SH3 fusion
proteins were eluted from the beads with 10 mM reduced glutathione in 50 mM Tris-HCl, pH 8.0. The eluted proteins
were dialyzed against 1× PBS at 4 °C overnight and stored at
-80 °C.
To obtain the thrombin-cleaved Grb2-N-SH3 fragment, the GST-Grb2-N-SH3
fusion protein was affinity-purified from 5 liters of bacterial culture
and dialyzed against 4 liters of 0.5× PBS at 4 °C, with two changes
over a period of 12 h, to remove the reduced glutathione. The
protein concentration of the dialyzed fusion protein was then diluted
to 0.4 mg/ml with 10 mM Tris-HCl, pH 8.0. Thrombin was
added to a final concentration of 10 units/mg protein, and the
digestion was allowed to proceed at room temperature for 36 h. The
digested mixture was filtered through a 0.22 µm filter and applied
onto a 1.0 × 5.0-cm glutathione-Sepharose column to remove the
larger GST fragment. The run-through solution containing the Grb2-N-SH3
fragment was concentrated using a 3000 MWCO membrane and further
purified by gel filtration on Sephadex 30 (2 × 50 cm)
equilibrated with 25 mM Tris-HCl, pH 8.0, 0.1 mM EDTA, pH 8.0, and 1 mM NaN3 at a
flow rate of 90 ml/h. Fractions of 3 ml were collected and analyzed by
SDS-PAGE. The Grb2-N-SH3 fragment eluted at about 125 ml. Fractions
containing Grb2-N-SH3 were pooled, concentrated, and stored at
-80 °C.
In Vitro GST-SH3 Binding Assay--
Approximately 5 µg of
total rMAP2c bacterial lysate, 1-2 µg of partially purified rMAP2c
(boiled, high salt bacterial supernatant), 1-2 µg of SP purified
rMAP2c, and 1 µg of phosphorylated or control-phosphorylated rMAP2c
were incubated with 5 µl of a 50% slurry of protein bound glutathione-Sepharose beads in a 200-µl volume containing 50 mM Tris-HCl, pH 7.5, 75 mM NaCl, 1 mM EDTA, 0.5 mM EGTA, 1 mM
dithiothreitol, 7.5 mM MgCl2, 5% glycerol, 1 mM Na3VO4, 0.5% bovine serum
albumin, and 1% Nonidet P-40 (Buffer C) at 4 °C for 2 h with
gentle mixing. In competition assays using HisTrxMTBD or HisTrx
proteins, 0.4 µg (80 nM) of rMAP2c was mixed with
increasing amounts of HisTrxMTBD or HisTrx protein (0.2-6
µM) and incubated with 0.8 µl of the 50% slurry of
protein bound glutathione-Sepharose beads in a final volume of 100 µl. In the binding assays in which rat brain or transfected COS-7
cell lysates were used, 0.3-1.0 mg of total lysate protein were
incubated with 40 µl of a 50% slurry of protein bound
glutathione-Sepharose beads in a final volume of 500 µl. The beads
were collected by centrifugation, washed twice with 1.3 ml of Buffer C
containing 150 mM NaCl, and washed a third time with Buffer
C at 150 mM NaCl but minus Nonidet P-40. The presence of
rMAP2c bound on the beads was analyzed by SDS-PAGE, followed by
immunoblotting using monoclonal anti-MAP2 antibody HM2 (1:1000). The
presence of histidine-tagged protein was detected by monoclonal
anti-polyhistidine antibody HIS-1 (1:3000).
Cell Cultures, Transfection, and Immunofluorescence
Microscopy--
COS-7 cells were maintained in Dulbecco's modified
Eagle's medium supplemented with 10% fetal bovine serum, 2 mM L-glutamine, and 2 mM pyruvate
at 37 °C in a humidified 5% CO2 atmosphere. When the
cultures reached approximately 80% confluency, they were transfected
with 8.5 µg of pEGFP-N1-MAP2c plasmid in the presence of 42 µl of
Superfect reagent for 3 h at 37 °C according to the manufacturer's protocol. Approximately 60-70 h posttransfection, cells were rinsed once in ice-cold 1× PBS and harvested in ice-cold lysis buffer (150 mM NaCl, 50 mM Tris-HCl, pH
7.5, 0.5% sodium deoxycholate, 1% Nonidet P-40, 1 mM
Na3VO4, 1 mM PMSF, 1 mM
NaF, 10 µg/ml aprotinin, 10 µg/ml pepstatin A, and 10 µg/ml
leupeptin). A pulse of sonication (Fisher Sonifer, setting 6, 5 s)
was given to ensure complete cell lysis, and the lysate was centrifuged at 13,500 × g for 30 min at 4 °C. Expression of the
rMAP2c-GFP fusion protein in the transfected COS-7 cells was verified
by immunoblot analysis using monoclonal anti-MAP2 antibody HM2. The clarified lysate was used in the GST-SH3 binding assay.
Preparation of dissociated rat hippocampal cultures from E18 rat
embryos, and growth and maintenance of these cultures were performed as
described (43). At 15 days in vitro, the cultures were
double-stained for MAP2 (HM2, 1:1000) and Src (sc-18, 1:1000), or MAP2
and Grb2 (sc-255, 1:1000) as described (43) using Alexa-568 conjugated
goat anti-rabbit IgG (1:1000) and Alexa-488 conjugated goat anti-mouse
IgG (1:1000) as secondary antibodies. Digital images were obtained
using a 60× oil immersion objective on an Olympus IX-70 microscope
coupled with a Photometrix PXL cooled CCD camera (43).
Preparation of Rat Brain Lysates--
Adult rat forebrain or
hippocampus and neonatal (postnatal day 1 (P1)) brain tissue were lysed
in 50 mM Tris-HCl, pH 7.5, 50 mM NaCl, 50 mM NaF, 5 mM Na3VO4, 5 mM EGTA, 5 mM EDTA, 1 mM dithiothreitol, 1% Nonidet P-40, 1 mM PMSF, 10 µg/ml
aprotinin, 10 µg/ml pepstatin A, and 10 µg/ml leupeptin at 4 °C.
The homogenates were sonicated to ensure complete lysis and centrifuged
as described above. The clarified brain lysates were used in the
GST-SH3 binding and co-immunoprecipitation assays.
Co-immunoprecipitation of MAP2 with Src or Grb2 from Rat Brain
Lysate--
Clarified brain lysates (1 mg of total protein) were
incubated with 25 µg of rabbit anti-Src (sc-18), rabbit anti-Grb2
(sc-255), rabbit anti-MAP2 (no.
4170),2 irrelevant IgG,
rabbit preimmune serum (no. 4170pis), or lysis buffer alone in a final
volume of 400 µl at 4 °C overnight with gentle mixing. A 100-µl
aliquot of a 50% slurry of protein A-Sepharose beads in 1× PBS and
1% bovine serum albumin was added, and the mixture was incubated at
4 °C for 1 h with gentle agitation. The beads were collected by
centrifugation at 4000 × g for 5 min, washed six times
briefly with 1 ml of 1× PBS, boiled in Laemmli SDS-sample buffer for 2 min (44), and analyzed by SDS-PAGE and immunoblotting.
In Vitro Phosphorylation of rMAP2c--
Phosphorylation
reactions were carried out in a 50-µl volume containing 50 mM HEPES, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 1 mM EGTA, 2 mM
dithiothreitol, 0.1 mM Na3VO4, 1 mM PMSF, 1 mM benzamidine, 1 mM
benzamide, 5 mM -caproic acid, 15 µg of rMAP2c, and 45 units of either PKA or MAPK (p42, extracellular signal-regulated kinase 2) or 12 units of GSK-3 , and 0.8 µM ATP with or
without 0.5 µCi of [ -32P]ATP (6000 Ci/mmol, NEN Life
Science Products) at 30 °C. At the indicated times, 13 µl were
removed and boiled at 95 °C for 5 min to terminate the reaction.
Samples were incubated on ice for 10 min and centrifuged at 13,500 × g for 15 min, and the supernatant collected was used in
the GST-SH3 binding assay described above. Control reactions were
carried out in the absence of added ATP.
Microtubule Binding Assay--
Microtubules were polymerized
from tubulin at a concentration of 5 mg/ml in assembly buffer (20 mM NaPO4, 100 mM
L-glutamate, 1 mM EGTA, 1 mM
MgCl2, and 1 mM GTP) and stabilized by 20 µM Taxol as described (45). Binding assay was performed
according to Ref. 46 using 1 µM full-length rMAP2c and 5 µM tubulin in an assay volume of 50 µl. The SDS-PAGE
gels were stained with Sypro Orange, and the fluorescence was
quantified on a FluorImager 595 (Molecular Dynamics, Sunnyvale, CA). In
assays in which GST, GST-Src-SH3, or Grb2-N-SH3 was added to the assay,
a 10 µM concentration of these proteins were used. Data
are expressed as a percentage of rMAP2c found in the microtubule pellet
fraction: (rMAP2c in pellet)/(rMAP2c in pellet + supernatant) × 100. One-way analysis of variance was used to assess statistical significance.
Protein Analytical Methods--
Protein concentrations were
determined by the BCA method (47) using bovine serum albumin as the
protein standard. Protein samples were analyzed by SDS-PAGE according
to Ref. 44 and visualized by Coomassie Brilliant Blue or Sypro Orange
staining. Electrotransfer and immunoblot analyses were performed as
described (48) using the respective primary antibodies and alkaline
phosphatase-conjugated or HRP-conjugated secondary antibodies. When
alkaline phosphatase-conjugated antibodies were used, the
5-bromo-4-chloro-3-indolyl phosphate/nitro blue tetrazolium
colorimetric detection method was used. When HRP-conjugated antibodies
were used, the chemiluminescence detection method was used.
 |
RESULTS |
Recombinant MAP2c Interacts Specifically with SH3 Domains of Src
and Grb2--
We hypothesized that other cellular proteins interact
with MAP2 in addition to those that have been reported thus far.
Analysis of the amino acid sequence of rat MAP2c, the smallest known
isoform of MAP2 (also known as juvenile MAP2 or embryonic MAP2, due to its perinatal expression pattern), revealed 13 PXXP motifs
distributed in several clusters in the amino-terminal two-thirds of the
molecule. These polyproline clusters lie within regions of unknown
function. Eleven of these PXXP motifs are conserved across
species and across alternatively spliced isoforms of MAP2. Because
PXXP is a known consensus motif of SH3 domain ligands (49),
we investigated the possibility that MAP2c would interact with a
variety of SH3 domain-containing proteins.
Using a GST-SH3 binding assay, we tested the ability of rMAP2c protein
in crude bacterial lysate to co-precipitate with SH3 domains of several
candidate proteins of varying cellular functions (Fig.
1). In this assay, the GST protein alone
did not precipitate any detectable amount of rMAP2c. However, rMAP2c
reliably co-precipitated together with GST-SH3 fusion proteins derived
from the protein tyrosine kinase Src and the adaptor protein Grb2 (Fig.
1A). In contrast, the SH3 domains of the protein tyrosine
kinase Abl, the adaptor protein Nck, and the GTPase activating protein
GAP exhibited little or no detectable binding to rMAP2c. Although the
fusion protein containing the second of the three SH3 domains in Nck,
GST-Nck-SH3(2), reproducibly precipitated trace amounts of rMAP2c,
neither the fusion protein containing the first SH3 domain Nck-SH3(1)
nor that containing both the second and third SH3 domains of Nck,
Nck-SH3(2 + 3), produced detectable binding with rMAP2c. This suggests
that perhaps the second SH3 domain of Nck was conformationally
inaccessible in the larger Nck-SH3(2 + 3) molecule. In addition to the
intact Grb2, the SH3 domains located at the amino and carboxyl termini
of Grb2 were analyzed independently. Grb2-N-SH3 exhibited stronger
binding than Grb2-C-SH3 and may well contribute to the majority of the
SH3 domain interaction observed for the intact Grb2.

View larger version (39K):
[in this window]
[in a new window]
|
Fig. 1.
Bacterially expressed recombinant MAP2c
interacts specifically with the SH3 domains of Src and Grb2.
In vitro GST-SH3 binding assay in which non-heat-denatured
rMAP2c bacterial lysate was incubated with GST or various GST-SH3
fusion proteins bound to glutathione-Sepharose beads and analyzed by
SDS-PAGE as described under "Experimental Procedures."
A, nitrocellulose immunoblot probed with anti-MAP2 antibody
HM2 and detected by colorimetric reaction. B, Coomassie
Brilliant Blue-stained 12% SDS-PAGE gel. Positions of rMAP2c, GST, and
assorted GST-SH3 fusion proteins are indicated at the right.
Positions of molecular size markers (in kDa) are indicated at the
left.
|
|
Both the recombinant and native forms of MAP2 are heat-stable and
retain their microtubule binding properties after being subjected to
high temperature (90-105 °C; 10 min) in the presence of high salt,
a step often used in the purification of MAP2 and other heat-stable
microtubule-associated proteins (50). As with microtubule binding, heat
treatment did not abolish the ability of rMAP2c to interact with SH3
domains. The same SH3 domain selectivity profile was observed for
rMAP2c partially purified from bacterial lysates via a high salt
boiling step and also for the subsequently SP-purified rMAP2c (data not
shown), suggesting that SH3 binding by MAP2c was not dependent on
heat-labile secondary structure.
MAP2 Isoforms Expressed in Mammalian Cells Interact with SH3
Domains of Src and Grb2--
Among the SH3 domains tested, we observed
that the Src and Grb2 SH3 domains gave specific and strongest binding
signals for rMAP2c in our GST-SH3 binding assay. We therefore proceeded
to analyze whether native isoforms of MAP2 expressed in eukaryotic cells behaved likewise. Recombinant MAP2c-GFP expressed in transfected COS-7 cells as well as both the high and low molecular weight isoforms
of MAP2 present in rat brain lysate specifically bound the SH3 domains
of Src and Grb2 (Fig. 2). In transfected
COS-7 cells, the rMAP2c-GFP fusion protein was highly expressed and was
detected as a doublet or a triplet of ~90-95 kDa (Fig.
2A), indicative of post-translational modification of the
GFP fusion protein in COS-7 cells. These posttranslationally modified
rMAP2c-GFPs from COS-7 cell lysate bound specifically to GST-Src-SH3
and GST-Grb2-N-SH3 (Fig. 2A). Adult rat brains express
predominantly the high molecular weight isoforms MAP2a and MAP2b, and
both of these isoforms were detected bound to GST-Src-SH3 and
GST-Grb2-N-SH3 (Fig. 2B). Insignificant trace amounts of
MAP2a and MAP2b were detected in GST alone control conditions.
Similarly, the high molecular weight isoform MAP2b and the low
molecular weight isoform MAP2c from neonatal rat brain lysate bound to
GST-Src-SH3, GST-Grb2, GST-Grb2-N-SH3, and GST-Grb2-C-SH3 but not to
GST (Fig. 2C).

View larger version (33K):
[in this window]
[in a new window]
|
Fig. 2.
Recombinant MAP2c-GFP fusion protein
expressed from transiently transfected COS-7 cells and native MAP2
isoforms from rat brain interact specifically with the SH3 domains of
Src and Grb2. In vitro GST-SH3 binding assays were
performed with transfected COS-7 cell lysates (A), adult rat
hippocampal lysate (B), and neonatal rat brain lysate
(C), as described under "Experimental Procedures." The
immunoblots were stained with anti-MAP2 antibody HM2 and detected by
colorimetric reaction. Positions of rMAP2c-GFP, various rat brain
isoforms of MAP2 (MAP2a, MAP2b, and MAP2c) are indicated at the
left. Positions of molecular size markers (in kDa) are
indicated at the right.
|
|
Co-immunoprecipitation of Endogenous MAP2 with Endogenous Src or
Grb2--
Results obtained from the in vitro GST-SH3
binding assay above strongly suggest that the SH3 domains of Src and
Grb2 could mediate direct association with MAP2. We next asked whether
endogenous Src or Grb2 also bind to native MAP2 by performing
co-immunoprecipitation experiments (Fig.
3). Under non-denaturing conditions,
antibodies to Src or Grb2 precipitated MAP2 isoforms in the immune
complexes. A fraction of MAP2 in the adult and neonatal rat brains
associated with Src or Grb2 and was found in the immunoprecipitates
(Fig. 3A, lanes 3, 4, 7, and 8). No MAP2 was
detected in a control immunoprecipitation experiment using an
irrelevant IgG (Fig. 3A, lane 5). Similarly, no detectable
MAP2 was bound on the protein A-Sepharose beads alone (Fig. 3A,
lane 6). In the reciprocal co-immunoprecipitation experiments
using rabbit anti-MAP2 antibody (no. 4170), Grb2 was found
co-precipitating with MAP2 in the immune complex (Fig. 3B, lane
2). Preimmune serum IgG precipitated no MAP2 and a negligible amount of Grb2 (Fig. 3B, lane 3). A similar experiment to
detect co-precipitation of Src using anti-MAP2 antibodies was not
interpretable due to interference of cross-reacting IgG bands in the
vicinity of Src on the blot.

View larger version (60K):
[in this window]
[in a new window]
|
Fig. 3.
Endogenous Src and Grb2 interact with native
MAP2 isoforms in rat brain. The interactions of endogenous Src and
Grb2 with native MAP2 proteins in rat brains were assessed by
co-immunoprecipitation as described under "Experimental
Procedures." A, the immunoblot was stained for MAP2 using
anti-MAP2 antibody HM2 and detected by colorimetric reaction
(lanes 1-6) or by the chemiluminescence method (lanes
7 and 8). Lane 1, adult rat hippocampal
lysate (20 µg); lane 2, neonatal P1 brain lysate (20 µg); lane 3, IP of hippocampal lysate with anti-Src
antibody sc-18; lane 4, IP of P1 brain lysate with anti-Src
antibody sc-18; lane 5, IP of hippocampal lysate with an
irrelevant IgG; lane 6, IP of hippocampal lysate without
added antibody; lane 7, IP of hippocampal lysate with rabbit
anti-Grb2 sc-255; lane 8, IP of P1 brain lysate with
anti-Grb2 antibody sc-255. B, reciprocal
co-immunoprecipitation assay of rat forebrain lysate using rabbit
anti-MAP2 (no. 4170) antibody. Immune complexes were separated on a
4-12% gradient gel, electroblotted onto nitrocellulose membrane, and
immunoblotted. The blot was divided and probed separately for MAP2 or
Grb2. The top blot was stained for MAP2 using anti-MAP2
antibody HM2, and the bottom blot was stained for Grb2 using
mouse anti-Grb2 antibody. Both blots were detected by the
chemiluminescence method. Lane 1, adult forebrain lysate (30 µg); lane 2, IP of adult forebrain lysate with rabbit
anti-MAP2 antibody (no. 4170); lane 3, IP of adult forebrain
lysate with rabbit preimmune serum (no. 4170pis). Positions of MAP2
isoforms and Grb2 are indicated at the left. Positions of
molecular size markers (in kDa) are indicated at the
right.
|
|
Native MAP2 from Rat Brains Are Not Phosphorylated on Tyrosine
Residues--
Because MAP2 from rat brain bound Src, we asked whether
endogenous MAP2 was a natural substrate of Src kinase activity.
In vitro, MAP2 is a substrate of the tyrosine kinases
insulin receptor kinase, epidermal growth factor receptor kinase, and
Src kinase (29-31). Native MAP2 and rMAP2c-GFP were immunoprecipitated
from rat brain and transfected COS-7 cells lysates, respectively, in the presence of the tyrosine phosphatase inhibitor sodium vanadate. The
immune complexes were separated on SDS-PAGE gels, transferred to
nitrocellulose membranes, and immunoblotted with three different anti-phosphotyrosine antibodies: P-Tyr-100, 4G10, and PY20-derived RC20-HRP. No detectable signal above background was observed for any of
these three antibodies (data not shown), suggesting that under our
experimental conditions, native MAP2 is not a substrate of Src or other
tyrosine kinases in vivo. These results were in agreement
with experiments in which phosphoamino acid analyses failed to detect
phosphotyrosine in MAP2 isolated from 32P-labeled rat
hippocampal slices (16).
MAP2, Src, and Grb2 Are Co-expressed in the Dendrites of Cultured
Neurons--
The results of the in vitro GST-SH3 binding
assays and the co-immunoprecipitation experiments strongly suggest that
MAP2 could indeed interact with Src and Grb2 in vivo. For
these interactions to occur in neurons, these proteins must be in close
proximity with each other. We proceeded to establish the distribution
and localization of these proteins in cultured rat hippocampal neurons. Neurons were double immunostained for MAP2 and Src or MAP2 and Grb2. As
described previously (51), MAP2 was found exclusively in the
somatodendritic compartment and was absent from axons (Fig. 4). Src immunoreactivity exhibited a
punctate distribution in the cell body, axons, and dendrites (Fig.
4A). Grb2 immunoreactivity was largely concentrated in the
cell body with modest levels throughout the dendrites; axons were
stained only weakly (Fig. 4B). Thus, MAP2, Src, and Grb2
were all present in neuronal cell bodies and dendrites, where they
could potentially engage in functional interactions.

View larger version (90K):
[in this window]
[in a new window]
|
Fig. 4.
MAP2, Src, and Grb2 proteins are co-expressed
in the dendrites of cultured neurons. Rat hippocampal neurons were
cultured at low density for 15 days in vitro and
double-stained for MAP2 and Src or for MAP2 and Grb2, as described
under "Experimental Procedures." A, neuron
double-stained for Src with anti-Src antibody sc-18 (left)
and for MAP2 with anti-MAP2 antibody HM2 (right). Src
immunoreactivity is present throughout the cell body, axons, and
dendrites. Axons are labeled only weakly. Arrowheads
indicate processes that are positive for Src immunoreactivity but
negative for MAP2, identifying them as axons. B, neuron
double-stained for Grb2 with anti-Grb2 antibody sc-255
(left) and for MAP2 with anti-MAP2 antibody HM2
(right). Grb2 immunoreactivity is strongest in the cell body
and moderate in the dendrites. The scale bar represents 20 µm.
|
|
The MTBD of rMAP2c Binds Src-SH3 and Grb2-N-SH3 Domains--
There
are 13 potential SH3 domain binding PXXP motifs arranged in
clusters in the amino-terminal two-thirds of the rat MAP2c, and 11 of
these PXXP motifs are conserved across species (Fig. 5A). To identify the Src-SH3
and Grb2-SH3 binding region in MAP2c, we created a series of
recombinant, non-fusion MAP2c proteins that have amino- or
carboxyl-terminal truncations or have internal deletions at the
polyproline-rich clusters (Fig. 5B). These mutants were
assessed for SH3 domain binding activity by the GST-SH3 binding assay.
All mutant MAP2c proteins were expressed at high levels in expression
host bacteria (10-20% of total protein), remained primarily in the
soluble fraction, and were purified from the soluble fraction by the
high salt boiling method (1) followed by SP ion exchange
chromatography. The rMAP2c in clarified bacterial lysates and
SP-purified rMAP2c were used separately in the GST-SH3 binding assays,
and both samples of rMAP2c proteins gave essentially similar results.
Surprisingly, the carboxyl-terminally truncated mutants that contained
all 13 potential SH3 domain binding PXXP motifs, 1-299 and
1-310, exhibited no detectable co-precipitation with GST-Src-SH3 or
GST-Grb2-N-SH3 in the GST binding assay (Fig. 5B). In
contrast, the amino-terminally truncated mutants, 154-476 and
296-467, efficiently co-precipitated with GST-Src-SH3 and GST-Grb2-N-SH3. The 296-467 MAP2c contains no PXXP motif.
These data suggest that binding of Src-SH3 and Grb2-N-SH3 domains by MAP2c did not involve PXXP motifs and that the binding
region resides elsewhere in the MAP2c molecule, possibly in the
carboxyl terminus. This hypothesis was verified using mutant MAP2c
proteins lacking specific polyproline-rich regions, amino acids
134-141, 219-290, and 290-297. All the polyproline-rich deletion
mutants were still able to bind to GST-Src-SH3 and GST-Grb2-N-SH3, and the observed binding of the mutant rMAP2c proteins was comparable to
that of the full-length rMAP2c (Fig. 5B). A candidate region in the carboxyl terminus of MAP2c that could contribute to SH3 domain
binding is the MTBD. A mutant 290-400 rMAP2c lacking both the
polyproline-rich cluster amino acids 290-297 and the MTBD was
constructed and tested for SH3 domain binding. The 290-400 rMAP2c
exhibited no detectable co-precipitation with GST-Src-SH3 and
GST-Grb2-N-SH3 in the GST-SH3 binding assay (Fig.
5B).

View larger version (34K):
[in this window]
[in a new window]
|
Fig. 5.
Mapping the region on MAP2c that binds
specifically to the SH3 domain of Src and Grb2. A,
schematic diagram of MAP2c showing the polyproline-rich clusters in the
amino-terminal two-thirds of the molecule. The amino acid sequences of
the 11 conserved SH3 domain-binding PXXP motifs are shown.
Other functional domains of MAP2c shown are the binding region for the
type II regulatory subunit (RII) of the
cAMP-dependent protein kinase (black box) near
the amino terminus (33, 34), and MTBD containing three imperfect
repeats (gray boxes) and inter-repeats near the carboxyl
terminus (7). B, summary of the interactions of the
full-length and the various mutant rMAP2c proteins with the SH3 domains
of Src and Grb2. The amino- or carboxyl-terminally truncated rMAP2c are
denoted by the amino acid residue positions corresponding to the
specific region on the full-length MAP2c that are present in the mutant
proteins (left). Mutants with internal deletion are denoted
by the region of amino acid residues that are removed. A positive
sign (+) indicates that there was detectable rMAP2
co-precipitation in the GST binding assay and that the amounts
co-precipitated were comparable to those observed for the full-length
rMAP2c. A negative sign (-) indicates that there was no
detectable co-precipitation with GST-SH3 fusion proteins.
ND, not determined. Results were compiled from at least
three independent GST-SH3 binding assays using different batches of
SP-purified rMAP2c proteins.
|
|
To further test that only the MTBD in rMAP2c contributes to Src-SH3 and
Grb2-SH3 domain binding, a recombinant MTBD, amino acids 300-400,
expressed as a histidine-tagged thioredoxin fusion protein
(HisTrxMTBD), was made. However, the leader fusion protein HisTrx
consistently gave a background of non-specific binding to the GST-SH3
fusion proteins used in the GST-SH3 binding assay. To circumvent this
problem, the purified HisTrxMTBD protein was used in competition with
the full-length rMAP2c in the GST-SH3 binding assay. If the MTBD in
rMAP2c specifically interacts with the SH3 domains of Src and Grb2, we
would expect a concentration-dependent inhibition of
full-length rMAP2c binding to the above-mentioned SH3 domains in the
presence of excess HisTrxMTBD but not in the presence of excess HisTrx.
Increasing concentrations of HisTrxMTBD significantly reduced the
amount of full-length rMAP2c co-precipitating with GST-Src-SH3 (Fig.
6A) or GST-Grb2-N-SH3 (Fig.
6B). At the same time, a corresponding increase of
HisTrxMTBD in the pellet with GST-Src-SH3 was detected (Fig.
6A). Increasing amounts of HisTrx had no effect on the
interaction of the full-length rMAP2c with the SH3 domains of Src (data
not shown) or Grb2 (Fig. 6C) as the amount of full-length
rMAP2c co-precipitated remained constant. Therefore, we conclude that
the Src-SH3 and Grb2-SH3 domain-binding region is localized to the
MTBD, amino acids 300-400 of MAP2c.

View larger version (39K):
[in this window]
[in a new window]
|
Fig. 6.
MAP2 microtubule-binding domain binds the SH3
domain of Src and Grb2. Recombinant MAP2c was incubated in the
absence or presence of an increasing amount HisTrxMTBD or HisTrx
proteins in the GST-SH3 binding assay. Proteins on the immunoblots were
detected by the chemiluminescence method. A, immunoblot of
proteins co-precipitated with GST-Src-SH3. The blot was divided and
probed separately for MAP2 using anti-MAP2 antibody HM2
(top) or stained for HisTrxMTBD using anti-polyhistidine
HIS-1 (bottom). B and C, immunoblots
of proteins co-precipitated with GST-Grb2-N-SH3. Blots were stained for
MAP2 using anti-MAP2 antibody HM2.
|
|
Src and Grb2 Bind Soluble Non-microtubule-bound MAP2--
Because
microtubules, Src-SH3 domain, and Grb2-SH3 domain bind within the same
region in MAP2c, we were interested to know whether these associations
were mutually or non-mutually exclusive. MAP2c-microtubule binding
assays were performed in the absence and presence of 10-fold molar
excess of GST or GST-Src-SH3. Because GST is known to form dimers (52,
53), the dimeric GST-Src-SH3 might be sterically excluded from the MTBD
in the presence of microtubules. We attempted to obtained the Src-SH3
and Grb2-N-SH3 fragments from the GST fusion proteins by thrombin
cleavage for use in this assay. Only the GST-Grb2-N-SH3 protein was
digestible by thrombin to liberate a larger, 27-kDa GST leader and a
smaller, 6-kDa Grb2-N-SH3 protein. The thrombin cleavage site between
the GST leader and Src-SH3 domain in GST-Src-SH3 fusion was presumed to
be eliminated during the construction of the expression vector. Under
the microtubule-binding experimental conditions, rMAP2c bound to
microtubules with an approximate stoichiometry of 1 mol of rMAP2c to 4 mol of tubulin dimer. No significant difference in rMAP2c binding to
microtubules was observed in the presence of excess GST, GST-Src-SH3,
or Grb2-N-SH3 (p 0.05; n = 5;
one-way analysis of variance) (Fig. 7).
We further determined whether microtubule-bound rMAP2c could mediate
GST-Src-SH3 co-precipitation in the presence of microtubules.
GST-Src-SH3 alone did not bind microtubules, and it did not
co-precipitate along with MAP2 in the microtubule pellet (data not
shown). These data indicate that microtubule binding and SH3 domain
binding are mutually exclusive and that rMAP2c shows preference to
microtubule binding even in the presence of excess Src-SH3 or
Grb2-N-SH3 domains. Thus, Src or Grb2 would interact with soluble,
non-microtubule-associated MAP2.

View larger version (14K):
[in this window]
[in a new window]
|
Fig. 7.
Recombinant MAP2c binds microtubules in the
presence of GST-Src-SH3 and Grb2-N-SH3. The microtubule binding
activity of full-length rMAP2c was determined in the absence and
presence of GST, GST-Src-SH3, and Grb2-N-SH3 proteins as described
under "Experimental Procedures." The supernatant and pellet samples
were analyzed by SDS-PAGE. The separated proteins were stained with
Sypro Orange and quantified by fluorometry. The data are presented as a
percentage of microtubule-bound rMAP2c over total rMAP2c. There was no
significant difference in rMAP2c binding to microtubules in the
presence of excess GST, GST-Src-SH3, or Grb2-N-SH3 (p 0.05; n = 5; one-way analysis of variance).
|
|
Phosphorylation of rMAP2c by MAPK Reduces Binding to Src and
Grb2--
MAP2 proteins isolated from brain tissues are highly and
differentially phosphorylated (16, 54, 55). Phosphorylation regulates
microtubule binding (56), and activity-dependent
phosphorylation and dephosphorylation of MAP2 have been observed
(15-20). Therefore, we tested the effects of phosphorylation on the
SH3 domain binding activity of MAP2. The cAMP-dependent
protein kinase (PKA) rapidly phosphorylated rMAP2c within 1 h
(Fig. 8A). In contrast, the
mitogen-activated, proline-directed protein kinase MAPK (extracellular
signal-regulated kinase 2, p42) achieved comparable phosphorylation of
rMAP2c after 8 h under similar kinase reaction conditions in
vitro (Fig. 8A). Under the conditions used, both
protein kinases maximally phosphorylate rMAP2c to a stoichiometry of
approximately 3 mol of
phosphate/mol.3 The
PKA-phosphorylated rMAP2c bound SH3 domains of Src and Grb2. All rMAP2c
incubated in the absence of ATP (as control-phosphorylated rMAP2c) also
bound SH3 domains of Src and Grb2 (Fig. 8, B and C). However, rMAP2c phosphorylated by MAPK for 8 h
exhibited significantly reduced interaction with the SH3 domains of
both Src and Grb2 (Fig. 8C).

View larger version (33K):
[in this window]
[in a new window]
|
Fig. 8.
Phosphorylation by MAPK (extracellular
signal-regulated kinase 2, p42) regulates rMAP2c association with SH3
domains of Src and Grb2. Recombinant MAP2c was incubated in the
absence (control) or presence of ATP and with either PKA or MAPK for
various times, as indicated, prior to use in the GST-SH3 binding.
Immunoblots were stained for MAP2c with anti-MAP2 antibody HM2 and
detected by colorimetric reaction. A, autoradiograph showing
time-dependent phosphorylation of rMAP2c by PKA or MAPK.
B, immunoblots of phosphorylated and mock-phosphorylated
(control) rMAP2c co-precipitated with GST-Src-SH3. C,
immunoblots of phosphorylated and control rMAP2c co-precipitated with
GST-Grb2-N-SH3. Results in B and C are
representative of three independent experiments.
|
|
Because MAPK is a proline-directed protein kinase, phosphorylation by
MAPK would theoretically occur at serine and threonine residues that
are adjacent to proline residues. To investigate whether
phosphorylation near proline residues is involved in regulating MAP2/SH3 domain interactions, proline-rich deletion mutant rMAP2c proteins were phosphorylated by MAPK for 8 h and then tested for SH3 domain binding. The SH3 domain binding activities of all
proline-rich deletion mutant rMAP2c proteins were inhibited by MAPK
phosphorylation (data not shown). In addition, full-length rMAP2c was
maximally phosphorylated using another proline-directed kinase GSK-3
for 24 h and analyzed for Src-SH3 and Grb2-N-SH3 domain binding
activity. The GSK-3 -phosphorylated rMAP2c demonstrated binding to
the selected SH3 domains that was comparable to that of the
full-length, non-phosphorylated rMAP2c (data not shown). Together,
these data suggest that the addition of phosphate groups to regions
other than the proline-rich areas in MAP2c regulate the interaction
with SH3 domains. Key phosphorylation sites may lie within the MTBD/SH3
domain-binding region itself.
In MAP2c, the MTBD/SH3 domain-binding region contains three
KXGS motifs that are targets of multiple kinases.
Phosphorylation of the serine residues in the KXGS motifs
abolishes microtubule binding in vitro (22). Furthermore,
full-length rMAP2c containing serine to glutamate mutations in the
KXGS motifs exhibit greatly reduced microtubule binding
in vivo.2 We tested the SH3 domain binding
activity of these mutants and found that they retained SH3 domain
binding activity in vitro that was indistinguishable from
that of the full-length, wild type rMAP2c (data not shown). This
observation indicates that phosphorylation at the KXGS
motifs in the MTBD is unlikely to modulate the binding of Src-SH3 and
Grb2-SH3 domains and that other candidate residues must be considered.
 |
DISCUSSION |
This study presents evidence of novel and direct interactions of
the intracellular signaling proteins Src and Grb2 with soluble, non-microtubule-bound MAP2 in neurons. These interactions were mediated
through the SH3 domains of Src and Grb2 and the MTBD of MAP2 and were
regulated by MAPK-dependent phosphorylation. Previous
studies showed that MAP2 is a substrate of MAPK in vivo (18,
19).
SH3 domains are well documented protein-protein interaction modules
found in multiple signaling pathways in cells, and they mediate
formation of large multiprotein complexes (57). MAP2c contains eleven
PXXP motifs that are conserved across species. The
PXXP motif has been demonstrated to be the minimum consensus ligand motif of SH3 domains (58). Surprisingly, none of the PXXP motifs in MAP2c were involved in binding the SH3
domains of Src or Grb2 under the described experimental conditions.
Instead, the SH3 domain-binding region in MAP2c was localized to the
same region responsible for microtubule binding, the MTBD, amino acids 300-400. However, it seems likely that the binding of microtubules versus SH3 domains to this region of MAP2 involve distinct
conformations, because serine to glutamate mutations in the
KXGS motifs that severely disrupt microtubule binding had no
effect on SH3 domain binding.
The related neuronal microtubule-associated protein tau was also
reported to bind the Src family of protein tyrosine kinases, Fyn, Lck,
and Src, through SH3 domains of the kinases (8). The Fyn-SH3
domain-binding site in tau was mapped to a proline-rich region of amino
acids 170-178, 170VVRTPPKSP178, in the
352-amino acid isoform of human tau. This region accounted for ~90%
of the Fyn-SH3 domain binding activity in tau (8). A similar sequence,
286IIRTPPKSP294, is also found in MAP2c (Fig.
9). However, this sequence does not
appear to participate in binding the SH3 domains of Src and Grb2,
because the 290-297 rMAP2c mutant bound to both Src-SH3 and
Grb2-N-SH3, and the binding activities were indistinguishable from
those of the full-length rMAP2c protein (Fig. 5B). The amino acids in the vicinity of 286IIRTPPKSP294 in
MAP2c differ from those of tau (Fig. 9). It is possible that neighboring amino acid composition influences the binding specificity of Src in MAP2c versus tau.

View larger version (46K):
[in this window]
[in a new window]
|
Fig. 9.
Amino acid sequence similarity between human
tau and rat MAP2c. Sequence alignment of the carboxyl half of the
human tau protein (GenBankTM accession number J03778) (73)
and rat neonatal MAP2c (GenBankTM accession number X17682)
(74). The boxed regions denote the imperfect repeats of the
MTBD, and the underlined region denotes the tyrosine kinase
Fyn-SH3 domain-binding region in the human tau protein (352-amino acid
isoform) (8). Note that this region is similar in both proteins,
although significant differences occur in the flanking regions.
|
|
Whereas PXXP motifs are ideal binding ligands for SH3
domains, non-proline-rich ligands have also been documented. For
example, the Sab protein preferentially associates with Bruton's
tyrosine kinase through a non-proline-rich sequence (59). Similarly, the c-Src-SH3 domain intramolecularly binds a stretch of 14 amino acids
(KPQTQGLAKDAWEI) in the SH2-kinase linker region in the molecule (60,
61). In an ideal PXXP-SH3 interaction, the PXXP ligand assumes a polyproline II left-handed helix such that the alternating proline and arginine residues make contact with tyrosine, tryptophan, and aspartate residues in the hydrophobic pocket of the SH3
domain (62, 63). In the inactive c-Src, the SH2-kinase linker region
adopts a partial pseudo-polyproline II left-handed helix conformation
and binds the SH3 domain to form an intramolecular interaction (60,
61). It is possible that certain regions in the MTBD of MAP2c assume a
similar pseudo-polyproline II left-handed helix conformation that is
capable of interacting with the hydrophobic pockets of Src-SH3 and
Grb2-SH3. Structural studies of the MTBD/SH3 domain complexes will be
needed to reveal the true nature of these interactions.
The fact that microtubules and the SH3 domains of Src and Grb2 bind to
the MTBD of MAP2c has two major implications. First, the 11 conserved
PXXP motifs on MAP2c remain available to interact with other
cellular proteins. With MAP2 acting as a scaffold protein for Src,
these proteins could become potential substrates for the MAP2c-bound
Src tyrosine kinase activity. Second, because microtubule binding and
SH3 domain binding are mutually exclusive, the non-microtubule-bound
pool of MAP2 could assume the additional physiological role of a
scaffold protein for Src and Grb2. Both microtubule binding and SH3
domain binding are regulated by phosphorylation. Differential
phosphorylation could presumably regulate the dual roles of MAP2
in vivo (scaffold versus cytoskeletal). Our data suggest that MAPK may regulate MAP2/Src/Grb2 interaction in
vivo. Phosphorylation within the three KXGS motifs in
the MTBD releases MAP2 from microtubules (22) and thus is predicted to
increase the pool of soluble MAP2 available for binding and organizing signaling molecules. In addition, a subpopulation of
non-microtubule-bound MAP2c is observed to co-localize with
microfilament-based structures in transfected cells2 and
neurons (64). This suggests that MAP2 could also function to shuttle
signaling molecules to the microfilament system in the dendrites of neurons.
Although MAP2 did not appear to be a target of Src in vivo,
other potential cellular substrates of Src in the dendrites include the
microtubules, microfilaments, and proteins directly or indirectly associated with MAP2. Phosphorylation could release Src from MAP2 to
augment an increase in membrane-associated Src at the growth cone. In
this way, MAP2-bound Src in developing dendrites might be directed to
regions of active microtubule dynamics, such as nerve growth cones, for
participation in neuronal morphogenesis. - and -tubulins, the
building blocks of microtubules, have been reported to be
phosphorylated by pp60c-Src at nerve growth cone membranes
(65). Because soluble MAP2 associates with microfilaments, actin and
actin-binding proteins could also be targeted by Src. For example,
F-actin and the actin-membrane linker protein ezrin are substrates of
tyrosine kinases in situ (66-68). Growth factor-induced
increases in protein tyrosine phosphorylation and a consequent
reorganization of the actin cytoskeleton are well documented (69).
Other proteins that bind MAP2, including the type II regulatory subunit
of PKA, calmodulin, and the mitochondrial outer membrane protein porin,
might also be substrates of Src. In addition, a
Src-dependent signaling cascade might affect other yet-to-be-identified proteins associated with MAP2 and the microtubule cytoskeleton. The adult isoforms of MAP2 are large molecules (~200 kDa), and the function of more than 90% of the molecule is still unknown. The binding of MAP2 with other proteins could occur via PXXP motifs or other regions in the molecule. These proteins
could then become substrates of Src. The discovery of new MAP2 binding partners would have implications for understanding the relationship between cell signaling and the neuronal cytoskeleton, particularly in
areas of neurite growth and synaptic plasticity.
Interactions of proteins with the adaptor protein Grb2 on MAP2 could
potentially generate multimeric signaling complexes on soluble MAP2.
Grb2 has two SH3 domains and a SH2 domain and is known to bridge
receptor and cytoplasmic tyrosine kinases with the Ras signaling
pathway and MAPK activation (70, 71). The amino-terminal SH3 domain
exhibited stronger binding to rMAP2c than the carboxyl-terminal SH3
domain. The amino-terminal SH3 domain could be MAP2-bound, leaving the
carboxyl-terminal SH3 domain free for binding other proteins. In
addition, the SH2 domain could bind tyrosine-phosphorylated proteins.
Thus, in vivo, Grb2 might mediate the indirect interaction
between MAP2 and cellular proteins, such as activated tyrosine kinases,
tyrosine phosphatases, and other adaptor molecules (57, 70-72).
Phosphorylation of MAP2 by MAPK would then release the multimeric
signaling complexes into the cytoplasmic compartment, and the complexes
could then join up with the appropriate effector molecules downstream
of the signaling cascades.
In conclusion, the demonstrated direct interactions between MAP2/Src
and MAP2/Grb2, and the proposed phosphorylation-dependent scaffolding role of MAP2 provide a plausible mechanism for modulation of the neuronal cytoskeleton by extracellular signals. The interaction also provides a mechanism for the local organization of signaling complexes in the neuron. Signal-dependent modulation of the
neuronal cytoskeleton is necessary during the growth of dendrites in
order to form intricate neural circuitry. Future experiments aimed at uncovering new proteins associated with MAP2 and the neuronal cytoskeleton will no doubt provide further insight into the
physiological significance of these novel interactions in the
developing nervous system.
 |
ACKNOWLEDGEMENTS |
We thank Dr. Gary M. Bokoch for gifts of
GST-SH3 expression E. coli; Dr. Klaus Hahn for the COS-7
cells; Rachel Ozer for the pEGFP-N1-MAP2c and the various serine
mutated rMAP2c plasmids; Arlene Hipolito for help with cell culture,
staining, and fluorescence microscopy; Amy Batinica for the
construction of the 219-290 rMAP2c expression plasmid; Dr. Brian
Ceresa for a gift RC20-HRP; Dr. Jawdat Al-bassam for bovine tubulin;
Dr. Jennifer Kowalski for assistance in purification of
Grb2-N-SH3-cleaved fragments; Camilo Orozco for expert computer
assistance; and Melissa Paine for help with the purification of
HisTrxMTBD protein.
 |
FOOTNOTES |
*
This work was supported by National Institutes of Health
Grant MH 50861 (to S. H.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
To whom correspondence should be addressed: Department of Cell
Biology, The Scripps Research Institute, 10550 N. Torrey Pines Rd., La
Jolla, CA 92037. Tel.: 858-784-2420; Fax: 858-784-2513; E-mail:
shelley@scripps.edu.
Published, JBC Papers in Press, April 25, 2000, DOI 10.1074/jbc.M001887200
2
R. Ozer and S. Halpain, submitted for publication.
3
A. Batinica and S. Halpain, unpublished data.
 |
ABBREVIATIONS |
The abbreviations used are:
MAP2, microtubule-associated protein 2;
MTBD, microtubule-binding domain;
PKA, protein kinase A;
MAPK, mitogen-activated protein kinase;
rMAP2c, recombinant bacterially expressed MAP2c;
SP, sulfopropyl;
HRP, horseradish peroxidase;
PMSF, phenylmethylsulfonyl fluoride;
GSK-3 , glycogen synthase kinase-3 ;
PBS, phosphate-buffered saline;
PAGE, polyacrylamide gel electrophoresis;
GST, glutathione
S-transferase;
HisTrx, histidine-tagged thioredoxin fusion
protein;
HisTrxMTBD, histidine-tagged thioredoxin-MTBD fusion protein;
IP, immunoprecipitate;
GFP, green fluorescent protein;
SH, Src
homology.
 |
REFERENCES |
| 1.
|
Gamblin, T. C.,
Nachmanoff, K.,
Williams, R. G.,
and Halpain, S.
(1996)
Biochemistry
35,
12576-12586
|
| 2.
|
Caceres, A.,
Mautino, J.,
and Kosik, K. S.
(1992)
Neuron
9,
607-618
|
| 3.
|
Johnson, G. V. W.,
and Jope, R. S.
(1992)
J. Neurosci. Res.
33,
505-512
|
| 4.
|
Lee, G.
(1993)
Curr. Opin. Cell Biol.
5,
88-94
|
| 5.
|
Hirokawa, N.
(1994)
Curr. Opin. Cell Biol.
6,
74-81
|
| 6.
|
Maccioni, R. B.,
and Cambiazo, V.
(1995)
Physiol. Rev.
75,
835-864
|
| 7.
|
Lewis, S. A.,
Wang, D. H.,
and Cowan, N. J.
(1988)
Science
242,
936-939
|
| 8.
|
Lee, G.,
Newman, T. S.,
Gard, D. L.,
Band, H.,
and Panchamoorthy, G.
(1998)
J. Cell Sci.
111,
3167-3177
|
| 9.
|
Sontag, E.,
Nunbhakdi-Craig, V.,
Lee, G.,
Bloom, G. S.,
and Mumby, M. C.
(1996)
Neuron
17,
1201-1207
|
| 10.
|
Liao, H.,
Li, Y.,
Brautigan, D. L.,
and Gundersen, G. G.
(1998)
J. Biol. Chem.
273,
21901-21908
|
| 11.
|
Sontag, E.,
Nunbhakdi-Craig, V.,
Lee, G.,
Brandt, R.,
Kamibayashi, C.,
Kuret, J.,
White III, C. L.,
Mumby, M. C.,
and Bloom, G. C.
(1999)
J. Biol. Chem.
274,
25490-25498
|
| 12.
|
Goedert, M.,
Jakes, R.,
Spillantini, M. G.,
Crowther, R. A.,
Cohen, P.,
Vanmechelen, E.,
Probst, A.,
Gotz, J.,
and Burki, K.
(1995)
Biochem. Soc. Trans.
23,
80-85
|
| 13.
|
Goedert, M.,
Crowther, R. A.,
and Spillantini, M. G.
(1998)
Neuron
21,
955-958
|
| 14.
|
Spillantini, M. G.,
and Goedert, M.
(1998)
Trends Neurosci.
21,
428-433
|
| 15.
|
Aoki, C.,
and Siekevitz, P.
(1985)
J. Neurosci.
5,
2465-2483
|
| 16.
|
Halpain, S.,
and Greengard, P.
(1990)
Neuron
5,
237-246
|
| 17.
|
Montoro, R. J.,
Diaz-Nido, J.,
Avila, J.,
and Lopez-Barneo, J.
(1993)
Neuroscience
54,
859-871
|
| 18.
|
Quinlan, E. M.,
and Halpain, S.
(1996)
Neuron
16,
357-368
|
| 19.
|
Quinlan, E. M.,
and Halpain, S.
(1996)
J. Neurosci.
16,
7627-7637
|
| 20.
|
Philpot, B. D.,
Lim, J. H.,
Halpain, S.,
and Brunjes, P. C.
(1997)
J. Neurosci.
17,
9596-9604
|
| 21.
|
Theurkauf, W. E.,
and Vallee, R. B.
(1983)
J. Biol. Chem.
258,
7883-7886
|
| 22.
|
Illenberger, S.,
Drewes, G.,
Trinczek, B.,
Biernat, J.,
Meyer, H. E.,
Olmsted, J. B.,
Mandelkow, E. M.,
and Mandelkow, E.
(1996)
J. Biol. Chem.
271,
10834-10843
|
| 23.
|
Sánchez, C.,
Tompa, P.,
Szücs, K.,
Friedrich, P.,
and Avila, J.
(1996)
Eur. J. Biochem.
241,
765-771
|
| 24.
|
Akiyama, T.,
Nishida, E.,
Ishida, J.,
Saji, N.,
Ogawara, H.,
Hoshi, M.,
Miyata, Y.,
and Sakai, H.
(1986)
J. Biol. Chem.
261,
15648-15651
|
| 25.
|
Berling, B.,
Willie, H.,
Roll, B.,
Mandelkow, E.-M.,
Garner, C.,
and Mandelkow, E.
(1994)
Eur. J. Cell Biol.
64,
120-130
|
| 26.
|
Goldenring, J. R.,
Vallano, M. L.,
and deLorenzo, R. J.
(1985)
J. Neurochem.
45,
900-905
|
| 27.
|
Goto, S.,
Yamamoto, H.,
Fukunaga, K.,
Iwasa, I.,
Matsukado, Y.,
and Miyamoto, E.
(1985)
J. Neurochem.
4,
276-283
|
| 28.
|
Yamamoto, H.,
Saitoh, Y.,
Fukunaga, K.,
Nishimura, H.,
and Miyamoto, E.
(1988)
J. Neurochem.
50,
1614-1623
|
| 29.
|
Kadowaki, T.,
Fujita-Yamaguchi, Y.,
Nishida, E.,
Takaku, F.,
Akiyama, T.,
Kathuria, S.,
Akanuma, Y.,
and Kasuga, M.
(1985)
J. Biol. Chem.
260,
4016-4020
|
| 30.
|
Akiyama, T.,
Kadowaki, T.,
Nishida, E.,
Kadooka, T.,
Ogawara, H.,
Fukami, Y.,
Sakai, H.,
Takaku, F.,
and Kasuga, M.
(1986)
J. Biol. Chem.
261,
14797-14803
|
| 31.
|
Nishida, E.,
Hoshi, M.,
Miyata, Y.,
Sakai, H.,
Kadowaki, T.,
Kasuga, M.,
Saijo, S.,
Ogawara, H.,
and Akiyama, T.
(1987)
J. Biol. Chem.
262,
16200-16204
|
| 32.
|
Vallee, R. B.,
DiBartolomeis, M. J.,
and Theukauf, W. E.
(1981)
J. Cell Biol.
90,
568-576
|
| 33.
|
Obar, R. A.,
Dingus, J.,
Bayley, H.,
and Vallee, R. B.
(1989)
Neuron
3,
639-645
|
| 34.
|
Rubino, H. M.,
Damerman, M.,
Shafit-Zagardo, B.,
and Erlichman, J.
(1989)
Neuron
3,
631-638
|
| 35.
|
Griffith, L. M.,
and Pollard, T. D.
(1978)
J. Cell Biol.
78,
958-965
|
| 36.
|
Griffith, L. M.,
and Pollard, T. D.
(1982)
J. Biol. Chem.
257,
9143-9151
|
| 37.
|
Sattilaro, R.
(1986)
Biochemistry
25,
2003-2009
|
| 38.
|
Cunningham, C. C.,
Leclerc, N.,
Flanagan, L. A.,
Lu, M.,
Janmey, P. A.,
and Kosik, K. S.
(1997)
J. Cell Biol.
136,
845-857
|
| 39.
|
Kotani, S.,
Nishida, E.,
Kumaga, i. H.,
and Sakai, H.
(1985)
J. Biol. Chem.
260,
10779-10783
|
| 40.
|
Lindén, M.,
and Karlsson, G.
(1996)
Biochem. Biophys. Res. Commun.
218,
833-836
|
| 41.
|
Sambrook, J.,
Fritsch, E. F.,
and Maniatis, T.
(1989)
Molecular Cloning: A Laboratory Manual
, 2nd Ed.
, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
|
| 42.
|
Sanger, F.,
Nicklen, S.,
and Coulson, A. R.
(1977)
Proc. Natl. Acad. Sci. U. S. A.
74,
5463-5467
|
| 43.
|
Halpain, S.,
Hipolito, A.,
and Saffer, L.
(1998)
J. Neurosci.
18,
9835-9844
|
| 44.
|
Laemmli, U. K.
(1970)
Nature
227,
680-685
|
| 45.
|
Butner, K. A.,
and Kirschner, M. W.
(1991)
J. Cell Biol.
115,
717-730
|
| 46.
|
Goode, B. L.,
and Feinstein, S. C.
(1994)
J. Cell Biol.
124,
769-782
|
| 47.
|
Smith, P. K.,
Krohn, R. I.,
Hermanson, G. T.,
Mallia, A. K.,
Gartner, F. H.,
Provenzano, M. D.,
Fujimoto, E. K.,
Goeke, N. M.,
Olson, B. J.,
and Klenk, D. C.
(1985)
Anal. Biochem.
150,
76-85
|
| 48.
|
Towbin, H.,
Staehelin, T.,
and Gordon, J.
(1979)
Proc. Natl. Acad. Sci. U. S. A.
76,
4350-4354
|
| 49.
|
Luttrell, L. M.,
Della Rocca, G. J.,
van Biesen, T.,
Luttrell, D. K.,
and Lefkowitz, R. J.
(1997)
J. Biol. Chem.
272,
4637-4644
|
| 50.
|
Sloboda, R. D.,
and Rosenbaum, J. L.
(1982)
Methods Enzymol.
85,
409-417
|
| 51.
|
Matus, A.,
Bernhardt, R.,
Bodmer, R.,
and Alaimo, D.
(1986)
Neuroscience
17,
371-389
|
| 52.
|
Mannervik, B.,
and Danielson, U. H.
(1988)
CRC Crit. Rev. Biochem.
23,
283-337
|
| 53.
|
Lundqvist, G.,
Yucel-Lindberg, T.,
and Morgenstern, R.
(1992)
Biochim. Biophys. Acta
1159,
103-108
|
| 54.
|
Tsuyama, S.,
Terayama, Y.,
and Matsuyama, S.
(1987)
J. Biol. Chem.
262,
10886-10892
|
| 55.
|
Walaas, S. I.,
and Nairn, A. C.
(1989)
J. Mol. Neurosci.
1,
117-127
|
| 56.
|
Brugg, B.,
and Matus, A.
(1991)
J. Cell Biol.
114,
735-743
|
| 57.
|
Birge, R. B.,
Knudsen, B. S.,
Besser, D.,
and Hanafusa, H.
(1996)
Genes Cells
1,
595-613
|
| 58.
|
Cheadle, C.,
Ivashchenko, Y.,
South, V.,
Searfoss, G. H.,
French, S.,
Howk, K.,
Ricca, G. A.,
and Jaye, M.
(1994)
J. Biol. Chem.
269,
24034-24039
|
| 59.
|
Mutsushita, M.,
Yamadori, T.,
Kato, S.,
Takemoto, Y.,
Inazawa, J.,
Baba, Y.,
Hashimoto, S.,
Sekine, S.,
Arai, S.,
Kunikata, T.,
Kurimoto, M.,
Kishimoto, T.,
and Tsukada, S.
(1998)
Biochem. Biophys. Res. Commun.
245,
337-343
|
| 60.
|
Xu, W.,
Harrison, S. C.,
and Eck, M. J.
(1997)
Nature
385,
595-602
|
| 61.
|
Sicheri, F.,
Moarefi, I.,
and Kuriyan, J.
(1997)
Nature
385,
602-609
|
| 62.
|
Goode, B. L.,
Denis, P. E.,
Panda, D.,
Radeke, M. J.,
Miller, H. P.,
Wilson, L.,
and Feinstein, S. C.
(1997)
Mol. Biol. Cell
8,
353-365
|
| 63.
|
Dalgarno, D. C.,
Botfield, M. C.,
and Rickles, R. J.
(1997)
Biopolymers
43,
383-400
|
| 64.
|
Morales, M.,
and Fifkova, E.
(1989)
Cell Tissue Res.
256,
447-456
|
| 65.
|
Matten, W. T.,
Aubry, M.,
West, J.,
and Maness, P. F.
(1990)
J. Cell Biol.
111,
1959-1970
|
| 66.
|
Schweiger, A.,
Mihalache, O.,
Ecke, M.,
and Gerisch, G.
(1992)
J. Cell Sci.
102,
601-609
|
| 67.
|
Howard, P. K.,
Sefton, B. M.,
and Firtel, R. A.
(1993)
Science
259,
241-244
|
| 68.
|
Jiang, W. G.,
Hiscox, S.,
Singhrao, S. K.,
Puntis, M. C.,
Nakamura, T.,
Mansel, R. E.,
and Hallett, M. B.
(1995)
Biochem. Biophys. Res. Commun.
217,
1062-1069
|
| 69.
|
Yin, H. L.,
and Stull, J. T.
(1999)
J. Biol. Chem.
274,
32529-32530
|
| 70.
|
Chardin, P.,
Cussac, D.,
Maignan, S.,
and Ducruix, A.
(1995)
FEBS Lett.
369,
47-51
|
| 71.
|
Schlessinger, J.
(1994)
Curr. Opin. Genet. Dev.
4,
25-30
|
| 72.
|
den Hertog, J.,
and Hunter, T.
(1996)
EMBO J.
15,
3016-3027
|
| 73.
|
Goedert, M.,
Wischik, C. M.,
Crowther, R. A.,
Walker, J. E.,
and Klug, A.
(1988)
Proc. Natl. Acad. Sci. U. S. A.
85,
4051-4055
|
| 74.
|
Doll, T.,
Papandrikopoulou, A.,
and Matus, A.
(1990)
Nucleic Acids Res.
18,
361
|
Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
B. Wu, B. Decourt, M. A. Zabidi, L. T. Wuethrich, W. H. Kim, Z. Zhou, K. MacIsaac, and D. M. Suter
Microtubule-mediated Src Tyrosine Kinase Trafficking in Neuronal Growth Cones
Mol. Biol. Cell,
November 1, 2008;
19(11):
4611 - 4627.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. H. Soltani, R. Pichardo, Z. Song, N. Sangha, F. Camacho, K. Satyamoorthy, O. P. Sangueza, and V. Setaluri
Microtubule-Associated Protein 2, a Marker of Neuronal Differentiation, Induces Mitotic Defects, Inhibits Growth of Melanoma Cells, and Predicts Metastatic Potential of Cutaneous Melanoma
Am. J. Pathol.,
June 1, 2005;
166(6):
1841 - 1850.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. P. Zamora-Leon, A. Bresnick, J. M. Backer, and B. Shafit-Zagardo
Fyn Phosphorylates Human MAP-2c on Tyrosine 67
J. Biol. Chem.,
January 21, 2005;
280(3):
1962 - 1970.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Phung-Koskas, A. Pilon, C. Pous, C. Betzina, M. Sturm, M.-L. Bourguet-Kondracki, G. Durand, and A. Drechou
STAT5B-mediated Growth Hormone Signaling Is Organized by Highly Dynamic Microtubules in Hepatic Cells
J. Biol. Chem.,
January 14, 2005;
280(2):
1123 - 1131.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. M. Salvador, M. P. Flynn, J. Avila, S. Reierstad, E. T. Maizels, H. Alam, Y. Park, J. D. Scott, D. W. Carr, and M. Hunzicker-Dunn
Neuronal Microtubule-associated Protein 2D Is a Dual A-kinase Anchoring Protein Expressed in Rat Ovarian Granulosa Cells
J. Biol. Chem.,
June 25, 2004;
279(26):
27621 - 27632.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Laurine, D. Lafitte, C. Gregoire, E. Seree, E. Loret, S. Douillard, B. Michel, C. Briand, and J.-M. Verdier
Specific Binding of Dehydroepiandrosterone to the N Terminus of the Microtubule-associated Protein MAP2
J. Biol. Chem.,
August 8, 2003;
278(32):
29979 - 29986.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Al-Bassam, R. S. Ozer, D. Safer, S. Halpain, and R. A. Milligan
MAP2 and tau bind longitudinally along the outer ridges of microtubule protofilaments
J. Cell Biol.,
June 24, 2002;
157(7):
1187 - 1196.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Belanger, C. A. Farah, M. D. Nguyen, M. Lauzon, S. Cornibert, and N. Leclerc
The projection domain of MAP2b regulates microtubule protrusion and process formation in Sf9 cells
J. Cell Sci.,
January 4, 2002;
115(7):
1523 - 1539.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. P. Zamora-Leon, G. Lee, P. Davies, and B. Shafit-Zagardo
Binding of Fyn to MAP-2c through an SH3 Binding Domain. REGULATION OF THE INTERACTION BY ERK2
J. Biol. Chem.,
October 19, 2001;
276(43):
39950 - 39958.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Fang, J. Hallman, N. Sangha, T. E. Kute, J. A. Hammarback, W. L. White, and V. Setaluri
Expression of Microtubule-Associated Protein 2 in Benign and Malignant Melanocytes : Implications for Differentiation and Progression of Cutaneous Melanoma
Am. J. Pathol.,
June 1, 2001;
158(6):
2107 - 2115.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. S. Ozer and S. Halpain
Phosphorylation-dependent Localization of Microtubule-associated Protein MAP2c to the Actin Cytoskeleton
Mol. Biol. Cell,
October 1, 2000;
11(10):
3573 - 3587.
[Abstract]
[Full Text]
|
 |
|
Copyright © 2000 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|